The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kurysheva N.I.

Oftal'mologicheskij tsentr Federal'nogo mediko-biologicheskogo agentstva, ul. Gamalei, 15, Moskva, Rossijskaja Federatsija, 123098

Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow (in Russian only)

Authors:

Kurysheva N.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2019;135(3): 113‑120

DOI: 10.17116/oftalma2019135031113

Read: 1914 times

Download PDF (RU)
Contact the author
Table of contents

SELECTIVE Α2 AGONISTS IN THE TREATMENT OF GLAUCOMA: NEUROPROTECTIVE PROPERTIES AND IMPACT ON OCULAR BLOOD FLOW (IN RUSSIAN ONLY)
SELECTIVE Α2 AGONISTS IN THE TREATMENT OF GLAUCOMA: NEUROPROTECTIVE PROPERTIES AND IMPACT ON OCULAR BLOOD FLOW (IN RUSSIAN ONLY)

To cite this article:

Kurysheva NI. Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow (in Russian only). Russian Annals of Ophthalmology. 2019;135(3):113‑120. (In Russ.)
https://doi.org/10.17116/oftalma2019135031113

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neuroprotective therapy for age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):152-158
The resu­lts of fistulizing glaucoma surgeries in pseudophackic patients. Russian Annals of Ophthalmology. 2025;(1):45-52
The role of the stru­cture of the lamina cribrosa in the diagnosis and treatment of glaucoma. Stru­ctural and circulatory changes in the lamina cribrosa with aging and elevated intraocular pressure. Russian Annals of Ophthalmology. 2025;(1):76-82
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Neurocytoprotection adva­nces in repe­rfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Abstract:

Glaucoma is the main cause of irreversible blindness in the world. The selective α2 adrenergic receptor agonist brimonidine holds an important place among the hypotensive eye drops. The second part of this review focuses on some important effects of brimonidine that characterizes it as a medication with direct neuroprotective multifactorial action, discusses its influence on ocular blood flow and highlights its capability to maintain normal autoregulation of ocular blood flow.

Keywords:

brimonidine
selective α2-adrenergic receptor agonist
glaucoma
neuroprotection
ocular blood flow

Authors:

Kurysheva N.I.

Oftal'mologicheskij tsentr Federal'nogo mediko-biologicheskogo agentstva, ul. Gamalei, 15, Moskva, Rossijskaja Federatsija, 123098

Close metadata

References:

  1. He S, Stankowska DL, Ellis DZ, Krishnamoorthy RR, Yorio T. Targets of neuroprotection in glaucoma. J Ocul Pharmacol. 2018;34(1-2):85-106. https://doi.org/10.1089/jop.2017.0041
  2. Sharif NA. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res. 2018;13(7):1145-1150. https://doi.org/10.4103/1673-5374.235017
  3. Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Experimental Eye Research. 2011;93(3):271-283. https://doi.org/10.1016/j.exer.2011.04.002
  4. Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidineepurite 0.15%. J Ocul Pharmacol Ther. 2006;22(4):242-246. https://doi.org/10.1089/jop.2006.22.242
  5. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005;89(6):758-763. https://doi.org/10.1136/bjo.2004.053025
  6. Mayor-Torroglosa S, De la Villa P, Rodríguez ME, López-Herrera MP, Avilés-Trigueros M, García-Avilés A, de Imperial JM, Villegas-Pérez MP, Vidal-Sanz M. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46(10):3825-3835. https://doi.org/10.1167/iovs.05-0392
  7. Hoffman WE, Kochs E, Werner C, Thomas C and Albrecht RF. Dexmedeto- midine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology. 1991;75(2):328-332.
  8. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration (published correction appears in Invest Ophthalmol Vis Sci. 1999;40(1):2470). Invest Ophthalmol Vis Sci. 1999;40(11):65-73.
  9. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1):216-223.
  10. Kamisaki Y, Hamahashi T, Hamada T, Maeda K, Itoh T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. Eur J Pharmacol. 1992;217(1):57-63.
  11. Lee D, Kim KY, Noh YH, Chai S, Lindsey JD, Ellisman MH et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One. 2012;7(10):e47098. https://doi.org/10.1371/journal.pone.0047098
  12. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain isch-aemia is mainly by reversed uptake. Nature (Lond). 2000;403(6767):316-321. https://doi.org/10.1038/35002090
  13. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49(10):4515-4522. https://doi.org/10.1167/iovs.08-2078
  14. Moreno MC, Campanelli J, Sande P, Sa’nez DA, Sarmiento MI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radical Biology & Medicine. 2004;37(6):803-812.
  15. Kurysheva NI, Vinetskaia MI, Erichev VP, Demchuk ML, Kuryshev SI. Contribution of free-radical reactions of chamber humor to the development of primary open-angle glaucoma. Vestnik oftal’mologii. 1996;112(4):3-5. (In Russ.)
  16. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25(5):490-513. https://doi.org/10.1016/j.preteyeres.2006.07.003
  17. Ozdemir G, Tolun FI, Gul M, Imrek S. Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation. J Glaucoma. 2009;18(9):662-665. https://doi.org/10.1097/IJG.0b013e31819c46b1
  18. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000;41(13):4169-4174.
  19. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of alpha-2 agonist pathway is neuroprotective in models of retina and optic nerve injury. Eur J Ophthalmol. 1999;9(suppl 1):17-21.
  20. Lee D, Kim KY, Noh YH, Chai S, Lindsey JD, Ellisman MH, et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One. 2012;7(10):e47098. https://doi.org/10.1371/journal.pone.0047098
  21. Lafuente MP, Villegas-Pérez MP, Sobrado-Calvo P, García-Avilés A, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia- induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42(9):2074-2084.
  22. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci. 2004;45(11):4049-4059. https://doi.org/10.1167/iovs.04-0490
  23. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32(1):42-50.
  24. Kojima K, Kitaoka Y, Munemasa Y, Hirano A, Sase K, Takagi H. Axonal protection by modulation of p62 expression in TNF-induced optic nerve degeneration. Neurosci Lett. 2014;581:37-41. https://doi.org/10.1016/j.neulet.2014.08.021
  25. Kitaoka Y, Kojima K, Munemasa Y, Sase K et al. Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration. Graefes Arch Clin Exp Ophthalmol. 2015;253(8):1291-1296. https://doi.org/10.1007/s00417-015-3005-3
  26. Lafuente López-Herrera MP, Mayor-Torroglosa S, Miralles de Imperial J, Villegas-Pérez MP, Vidal-Sanz M. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol. 2002;178(2):243-258.
  27. Prokosch V, Panagis L, Volk GF, Dermon C, Thanos S. Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants. Invest Ophthalmol Vis Sci. 2010;51(12):6688-6699. https://doi.org/10.1167/iovs.09-4835
  28. Fujita Y, Sato A, Yamashita T. Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation. Cell Death Dis. 2013;4:e763. https://doi.org/10.1038/cddis.2013.298
  29. Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE. Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci. 2007;48(11):5085-5090. https://doi.org/10.1167/iovs.06-1249
  30. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA. 2007;104(33):13444-13449. https://doi.org/10.1073/pnas.0703707104
  31. Nizari S, Guo L, Davis BM, Normando EM, et al. Non-amyloidogenic effects of b2 adrenergic agonists: implications for brimonidine-mediated neuroprotection. Cell Death Dis. 2016;7(12):e2514. https://doi.org/10.1038/cddis.2016.397
  32. Ferencz JR, Gilady G, Harel O, Belkin M, Assia EI. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243(9):877-880. https://doi.org/10.1007/s00417-005-1160-7
  33. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br J Ophthalmol. 2003;87(12):1463-1465.
  34. Gandolfi SA, Sangermani C, Cimino L, Ungaro N, Tardini M, Viswanathan A, et al. Is there a non-IOP related effect of brimonidine on visual field progression in human glaucoma? Invest Ophthalmol Vis Sci. 2004;45: ARVO E-Abstract: 2298.
  35. Lee KYC, Nakayama M, Aihara M, Chen Y-N, Araie M. Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells. Mol Vis. 2010;16:246-251.
  36. Alblas J, van Corven EJ, Hordijk PL, Milligan G, Moolenaar WH. Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. J Biol Chem. 1993;268(30):22235-22238.
  37. Semba K, Namekara K, Kimura A, Harada C, Mitamura Y, Harada T. Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma. Cell Death and Disease. 2014;5e1341. https://doi.org/10.1038/cddis.2014.306
  38. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797-803.
  39. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001;108(4):784-787.
  40. Ruiz Lapuente C, Ruiz Lapuente A, Link B. Influence of topical brimonidine on visual field in glaucoma. Eur J Ophthalmol. 2001;11(suppl 2):67-71.
  41. Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocul Pharmacol Ther. 2005;21(6):475-482. https://doi.org/10.1089/jop.2005.21.475
  42. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. Low-pressure glaucoma study group. The low-pressure glaucoma treatment study (LoGTS). Study design and baseline characteristics of enrolled patients. Ophthalmology. 2005;112(3):376-385. https://doi.org/10.1016/j.ophtha.2004.10.034
  43. Krupin T, Liebmann J, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671-681. https://doi.org/10.1016/j.ajo.2010.09.026
  44. Sena D, Lindsle K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;(2):CD006539. https://doi.org/10.1002/14651858.CD006539.pub4
  45. Aung T, Oen FT, Wong HT, Chan YH, Khoo BK, Liu YP, Ho CL, See J, Thean LH, Viswanathan AC, Seah SK, Chew PT. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Br J Ophthalmol. 2004;88(1):88-94.
  46. Harris A, Jonescu-Cuypers CP. The impact of glaucoma medication on parameters of ocular perfusion. Curr Opin Ophthalmol. 2001;12(2):131-137.
  47. Moore, Harris A, Wudunn D, Kheradiya N, Siesky B. Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma? Clin Ophthalmol. 2008;2(4):849-861.
  48. Kurysheva NI, Maslova EV, Zolnikova IV, Fomin AV, Lagutin MB. A comparative study of structural, functional and circulatory parameters in glaucoma diagnostics. PLoS ONE. 2018;13(8):e0201599. https://doi.org/10.1371/journal.pone.0201599
  49. Sebastiani A, Parmeggiani F, Costagliola C, Ciancaglini M, D’Oronzo E, Mastropasqua L. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. Acta Ophthalmol Scand Suppl. 2002;236:29-30.
  50. Rosa Jr RH, Hein TW, Yuan Z, Xu W, Pechal MI, Geraets RL, Newman JM, Kuo L. Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small. Am J Physiol Heart Circ Physiol. 2006;291(1):231-238. https://doi.org/10.1152/ajpheart.01281.2005
  51. Carlsson AM, Chauhan BC, Lee AA, Leblanc RP. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected]. Am J Ophthalmol. 1999;128(6):697-701.
  52. Costagliola C, Parmeggiani F, Ciancaglini M, D’Oronzo E, Mastropasqua L, Sebastiani A. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica. 2003;217(1):39-44. https://doi.org/10.1159/000068249
  53. Yu M, Li Y, Liu X, Ling Y, Zheng X. Effect of 0.2% brimonidine on retinal blood flow. Yan Ke Xue Bao. 2001;17(1):42-45.
  54. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol. 1998;116(12):1591-1594.
  55. Schmidt KG, Klingmuller V, Gouveia SM, Osborne NN, Pillunat LE. Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients. Am J Ophthalmol. 2003;136(6):1038-1048.
  56. Reitsamer HA, Posey M, Kiel JW. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res. 2006;82(3):405-415. https://doi.org/10.1016/j.exer.2005.07.015
  57. Feke G, Hazin R. Effect of Brimonidine on Retinal Blood Flow autoregulation in Primary open-angle glaucoma. Journal of ocular pharmacology and therapeutics. 2011;27(4):347-352. https://doi.org/10.1089/jop.2011.0014
  58. Ulrich A, Ulrich C, Barth T, Ulrich WD. Detection of disturbed autoregulation of the peripapillary choroid in primary open angle glaucoma. Ophthalmic Surg Lasers. 1996;27(9):746-757.
  59. Fuchsjager-Mayrl G, Wally B, Georgopoulos M, et al. Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci. 2004;45(3):834-839.
  60. Tutaj M, Brown CM, Br, et al. Dynamic cerebral autoregulation is impaired in glaucoma. J Neurol Sci. 2004;220(1-2):49-54. https://doi.org/10.1016/j.jns.2004.02.002
  61. Furlanetto RL, DeMoraes CG, Teng CC, Low-Pressure Glaucoma Treatment Study Group. Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2014;157(5):945-952. https://doi.org/10.1016/j.ajo.2014.02.009
  62. European glaucoma society terminology and guidelines for glaucoma, 4th Edition — Chapter 3: treatment principles and options. Supported by the EGS Foundation. Br J Ophthalmol. 2017;101:130-195.
  63. Oh DJ, Chen JL, Vajaranant TS, Dikopf MS. Brimonidine tartrate for the treatment of glaucoma. Expert Opin Pharmacother. 2018;8:1-8. https://doi.org/10.1080/14656566.2018.1544241
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.